Non-metabolic functions of glycolytic enzymes in tumorigenesis

Oncogene

Volumn 36, Issue 19, 2017, Pages 2629-2636

  Yu, X ^a   Li, S ^a  

^a HUBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOLYTIC ENZYME; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PENTOSE PHOSPHATE; PROTEIN KINASE; ENZYME; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; CARCINOGENESIS; CHROMATIN; DNA MODIFICATION; GENETIC TRANSCRIPTION; GLYCOLYSIS; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HUMAN; MACROMOLECULE; METABOLIC REGULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; CITRIC ACID CYCLE; ENZYMOLOGY; GENETICS; NEOPLASM; OXIDATIVE PHOSPHORYLATION; PATHOLOGY;

APOPTOSIS; CARCINOGENESIS; CITRIC ACID CYCLE; ENZYMES; GLYCOLYSIS; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84992699719     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.410     Document Type: Review

References (85)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
2. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68-72.
3. Kennedy KM, Scarbrough PM, Ribeiro A, Richardson R, Yuan H, Sonveaux P et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PloS One 2013; 8: e75154.
4. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 2011; 9: 298-310.
5. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci 2014; 39: 191-198.
6. Stincone A, Prigione A, Cramer T, Wamelink MM, Campbell K, Cheung E et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc 2015; 90: 927-963.
7. Lincet H, Icard P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene 2015; 34: 3751-3759.
8. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-228.
9. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA 3rd et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012; 337: 975-980.
10. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334: 1278-1283.
11. Gruning NM, Rinnerthaler M, Bluemlein K, Mulleder M, Wamelink MM, Lehrach H et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab 2011; 14: 415-427.
12. Li S, Swanson SK, Gogol M, Florens L, Washburn MP, Workman JL et al. Serine and SAM Responsive Complex SESAME Regulates Histone Modification Crosstalk by Sensing Cellular Metabolism. Mol Cell 2015; 60: 408-421.
13. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005; 30: 142-150.
14. Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 2003; 10: 1535-1551.
15. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003; 107: 707-714.
16. Colell A, Ricci JE, Tait S, Milasta S, Maurer U, Bouchier-Hayes L et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007; 129: 983-997.
17. Tarze A, Deniaud A, Le Bras M, Maillier E, Molle D, Larochette N et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 2007; 26: 2606-2620.
18. Fan J, Krautkramer KA, Feldman JL, Denu JM. Metabolic regulation of histone post-translational modifications. ACS Chem Biol 2015; 10: 95-108.
19. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16: 9-17.
20. Ryall JG, Cliff T, Dalton S, Sartorelli V. Metabolic Reprogramming of Stem Cell Epigenetics. Cell Stem Cell 2015; 17: 651-662.
21. Li S, Kong L, Yu X, Zheng Y. Host-virus interactions: from the perspectives of epigenetics. Rev Med Virol 2014; 24: 223-241.
22. Boukouris AE, Zervopoulos SD, Michelakis ED. Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription. Trends Biochem Sci 2016; 41: 712-730.
23. Huang X, Holden HM, Raushel FM. Channeling of substrates and intermediates in enzyme-catalyzed reactions. Ann Rev Biochem 2001; 70: 149-180.
24. Matsuda S, Adachi J, Ihara M, Tanuma N, Shima H, Kakizuka A et al. Nuclear pyruvate kinase M2 complex serves as a transcriptional coactivator of arylhydrocarbon receptor. Nucleic Acids Res 2016; 44: 636-647.
25. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A et al. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 2014; 158: 84-97.
26. Ventura M, Mateo F, Serratosa J, Salaet I, Carujo S, Bachs O et al. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation. Int J Biochem Cell Biol 2010; 42: 1672-1680.
27. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280: 36334-36341.
28. Castonguay Z, Auger C, Thomas SC, Chahma M, Appanna VD. Nuclear lactate dehydrogenase modulates histone modification in human hepatocytes. Biochem Biophys Res Commun 2014; 454: 172-177.
29. Zheng L, Roeder RG, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003; 114: 255-266.
30. Katoh Y, Ikura T, Hoshikawa Y, Tashiro S, Ito T, Ohta M et al. Methionine adenosyltransferase II serves as a transcriptional corepressor of Maf oncoprotein. Mol Cell 2011; 41: 554-566.
31. Kera Y, Katoh Y, Ohta M, Matsumoto M, Takano-Yamamoto T, Igarashi K. Methionine adenosyltransferase II-dependent histone H3K9 methylation at the COX-2 gene locus. J Biol Chem 2013; 288: 13592-13601.
32. Li S, Shogren-Knaak MA. Cross-talk between histone H3 tails produces cooperative nucleosome acetylation. Proc Natl Acad Sci USA 2008; 105: 18243-18248.
33. Li S, Shogren-Knaak MA. The Gcn5 bromodomain of the SAGA complex facilitates cooperative and cross-tail acetylation of nucleosomes. J Biol Chem 2009; 284: 9411-9417.
34. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174: 1619-1628.
35. Friis RM, Wu BP, Reinke SN, Hockman DJ, Sykes BD, Schultz MC. A glycolytic burst drives glucose induction of global histone acetylation by picNuA4 and SAGA. Nucleic Acids Res 2009; 37: 3969-3980.
36. McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K et al. Histone acetylation regulates intracellular pH. Mol Cell 2013; 49: 310-321.
37. Liu XS, Little JB, Yuan ZM. Glycolytic metabolism influences global chromatin structure. Oncotarget 2015; 6: 4214-4225.
38. Cai L, Sutter BM, Li B, Tu BP. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 2011; 42: 426-437.
39. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 2006; 66: 11560-11564.
40. Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ et al. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res 2012; 40: 4794-4803.
41. Su X, Wellen KE, Rabinowitz JD. Metabolic control of methylation and acetylation. Curr Opin Chem Biol 2016; 30: 52-60.
42. Ringel AE, Ryznar R, Picariello H, Huang KL, Lazarus AG, Holmes SG. Yeast Tdh3 (glyceraldehyde 3-phosphate dehydrogenase) is a Sir2-interacting factor that regulates transcriptional silencing and rDNA recombination. PLoS Genet 2013; 9: e1003871.
43. Xu YF, Zhao X, Glass DS, Absalan F, Perlman DH, Broach JR et al. Regulation of yeast pyruvate kinase by ultrasensitive allostery independent of phosphorylation. Mol Cell 2012; 48: 52-62.
44. Wilson MJ, Shivapurkar N, Poirier LA. Hypomethylation of hepatic nuclear DNA in rats fed with a carcinogenic methyl-deficient diet. Biochem J 1984; 218: 987-990.
45. Tanaka Y, Yano H, Ogasawara S, Yoshioka S, Imamura H, Okamoto K et al. Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation. Mol Cell Biol 2015; 35: 4170-4184.
46. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alphaketoglutarate maintains the pluripotency of embryonic stem cells. Nature 2015; 518: 413-416.
47. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685-696.
48. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003; 278: 15333-15340.
49. Johnson C, Warmoes MO, Shen X, Locasale JW. Epigenetics and cancer metabolism. Cancer Lett 2015; 356: 309-314.
50. Galdieri L, Zhang T, Rogerson D, Vancura A. Reduced histone expression or a defect in chromatin assembly induces respiration. Mol Cell Biol 2016; 36: 1064-1077.
51. Mehrotra S, Galdieri L, Zhang T, Zhang M, Pemberton LF, Vancura A. Histone hypoacetylation-activated genes are repressed by acetyl-CoA- and chromatinmediated mechanism. Biochim Biophys Acta 2014; 1839: 751-763.
52. Keller KE, Doctor ZM, Dwyer ZW, Lee YS. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol Cell 2014; 53: 700-709.
53. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 2012; 45: 598-609.
54. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 2000; 473: 47-52.
55. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 2008; 40: 1043-1054.
56. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732-744.
57. Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J 2015; 34: 1349-1370.
58. Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S et al. Increased expression of the autocrine motility factor is associated with poor prognosis in patients with clear cell-renal cell carcinoma. Medicine 2015; 94: e2117.
59. Fairbank M, St-Pierre P, Nabi IR. The complex biology of autocrine motility factor/ phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase. Mol Biosyst 2009; 5: 793-801.
60. Araki K, Shimura T, Yajima T, Tsutsumi S, Suzuki H, Okada K et al. Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 2009; 284: 32305-32311.
61. Niinaka Y, Harada K, Fujimuro M, Oda M, Haga A, Hosoki M et al. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res 2010; 70: 9483-9493.
62. Kho DH, Zhang T, Balan V, Wang Y, Ha SW, Xie Y et al. Autocrine motility factor modulates EGF-mediated invasion signaling. Cancer Res 2014; 74: 2229-2237.
63. Kho DH, Nangia-Makker P, Balan V, Hogan V, Tait L, Wang Y et al. Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res 2013; 73: 1411-1419.
64. Fu M, Li L, Albrecht T, Johnson JD, Kojic LD, Nabi IR. Autocrine motility factor/ phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release. Cell Death Differ 2011; 18: 1057-1070.
65. Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y et al. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Br J Cancer 2015; 112: 1332-1339.
66. Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y et al. Mitochondriatranslocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol Cell 2016; 61: 705-719.
67. He CL, Bian YY, Xue Y, Liu ZX, Zhou KQ, Yao CF et al. Pyruvate kinase M2 Activates mTORC1 by phosphorylating AKT1S1. Sci Rep 2016; 6: 21524.
68. Kong L, Li S, Yu X, Fang X, Xu A, Huang M et al. Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response. Arch Virol 2016; 161: 2149-2159.
69. Adams V, Griffin LD, Gelb BD, McCabe ER. Protein kinase activity of rat brain hexokinase. Biochem Biophys Res Commun 1991; 177: 1101-1106.
70. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
71. Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH et al. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol 2009; 29: 3991-4001.
72. Zhang JY, Zhang F, Hong CQ, Giuliano AE, Cui XJ, Zhou GJ et al. Critical protein GAPDH and its regulatory mechanisms in cancer cells. Cancer Biol Med 2015; 12: 10-22.
73. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.
74. Gong L, Wei Y, Yu X, Peng J, Leng X. 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findings. Anti-Cancer Agents Med Chem 2014; 14: 771-776.
75. Ros S, Schulze A. Balancing glycolytic flux: the role of 6-phosphofructo-2- kinase/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab 2013; 1: 8.
76. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685-3692.
77. Khalid MH, Shibata S, Hiura T. Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg 1999; 90: 918-927.
78. Penso J, Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 1998; 342: 113-117.
79. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 2012; 8: 839-847.
80. Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC et al. The MCT4 gene: a novel, potential target for therapy of advanced prostate cancer. Clin. Cancer Res. 2016; 22: 2721-2733.
81. Olson KA, Schell JC, Rutter J. Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies. Trends Biochem Sci 2016; 41: 219-230.
82. Gancedo JM. Yeast carbon catabolite repression. Microbiol Mol Biol Rev 1998; 62: 334-361.
83. Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta 1998; 1397: 102-117.
84. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell 2014; 53: 75-87.
85. Grosse F, Nasheuer HP, Scholtissek S, Schomburg U. Lactate dehydrogenase and glyceraldehyde-phosphate dehydrogenase are single-stranded DNA-binding proteins that affect the DNA-polymerase-alpha-primase complex. Eur J Biochem/ FEBS 1986; 160: 459-467.